Chelsea Therapeutics has enrolled 118 randomised patients for Study 301, the second of two pivotal Phase III clinical trials in Chelsea’s registration program of Droxidopa for the treatment
Targeted Genetics has sold certain assets, including manufacturing technologies and other adeno-associated viral (AAV) vector technology to Genzyme for $7m in cash. The company said, purchased assets consist
Biovista has reported that BVA-201, a drug targeting Multiple Sclerosis (MS), has shown positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is
Cumberland Pharmaceuticals has launched Caldolor, an intravenous formulation of ibuprofen, designed primarily for use in the hospitals. The company said, Caldolor is an injectable product for the treatment
Germany-based Merck has acquired Suzhou Taizhu Technology Development Co. (Taizhu), a supplier of effect pigments located in Taicang near Shanghai, China. The acquisition is said to of high
“This latest distribution agreement with AXA Diagnostics marks Rosetta Genomics’ entry into Europe, and we are excited to have AXA as our first partner in this region,” noted
Amarillo Biosciences has announced that a phase 2 study of orally administered interferon-alpha for the prevention of influenza and winter colds has reached the midway point. The study
Zinc finger nucleases (ZFNs), designed by Sangamo, is used by scientists to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem
India-based Cipla, is planing to initiate production of biotechnology medicines in the near future, reported business standard. The company will be setting up a joint venture with a
Genzyme has announced plans to launch three products in India, reported Indian Express Finance. The company’s two products, an adhesion barrier that reduces complications after post-abdominal and gynaecological
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.